Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NxThera

Explore full profile

Medical device to improve urinary flow of men and develops patient quality of life

Maple Grove, United StatesFounded 2008Biotech & Life Sciences
Valuation $250–500M Last recorded · 2018
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NxThera and the history behind them.

About NxThera

There appears to be a mix-up between two separate companies named NxThera.

Read full description

The first, a UK-based company now part of Verint Systems, specializes in automated compliance and assurance technologies. This firm focuses on the financial sector, providing solutions that ensure the accurate recording and retention of complex communications like voice, data, and text. Serving top global investment banks, Nxtera's software automates the monitoring and testing of communication and recording services to meet evolving regulatory requirements. Its product suite, which includes Proof, Parity, Reflect, Retrieve, and Verify, offers compliance assurance, testing, and operational intelligence. The business model centers on alleviating compliance stress for financial institutions by delivering real-time operational confirmation and regulatory evidence, thus preventing costly fines and reputational damage. The company generates revenue by selling its software solutions and forming channel partnerships.

The second, a US-based medical device company from Maple Grove, Minnesota, was founded in 2008 by Michael Hoey. This NxThera pioneered the use of convective water vapor energy to treat urological conditions, most notably benign prostatic hyperplasia (BPH). The founder's journey was deeply personal, driven by his father's battle with prostate cancer and the severe side effects of traditional treatments. A significant milestone was achieved in 2015 when its Rezūm™ System received FDA clearance. This system uses radiofrequency energy to convert water into vapor, which is then used to ablate obstructive prostate tissue in a minimally invasive procedure. The company successfully raised approximately $148 million in funding over 12 rounds from investors including Aberdare Ventures and Arboretum Ventures. In March 2018, Boston Scientific acquired this NxThera for an upfront payment of $306 million, with potential for an additional $100 million in milestones. As part of the acquisition, the technology's application for treating cancer was spun off into a new entity. Keywords: regulatory compliance, communication recording, compliance assurance, financial services technology, automated testing, operational intelligence, trade surveillance, Verint, compliance monitoring, risk management, medtech, urology, benign prostatic hyperplasia, BPH, water vapor therapy, Rezūm System, Michael Hoey, Boston Scientific, medical devices, minimally invasive surgery, prostate treatment, endourology, convective energy

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2008
Headquarters
Maple Grove, United States
Employees
4
Open positions
None listed
Dealroom signal
59.7/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Patient Care, Mentech, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Mar 2018 $306M $306M Boston Scientific —
DEBTDebt Jul 2017 $6M — Undisclosed —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

NxThera website traffic

Latest recorded traffic for NxThera is 410 monthly website visits, down 4.7% over the last three months. NxThera's team declined 20% over the past year.

Latest monthly visits410 3-month web change-4.7% 1-year team growth-20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Veran Medical TechnologiesImage-guided medical device company that helps physicians diagnose disease and deliver therapies Overland, United States Acquired 26 $55M $340M
IceCure MedicalDevelops and markets minimally invasive cryoablation therapies for the treatment of breast cancer Caesarea, Israel Operational
POC Medical Systems Inc.Home - POC Medical Systems Livermore, United States Operational
P-CureP-Cure is a biotech company has developed a patient centric proton therapy solution with clinical benefits and financial advantages Shilat, Israel Operational
DiaCartaImproving patient care through novel precision molecular diagnostics: CE/IVD marked tests are available for detection of KRAS Hayward, United States Operational
TARGETED DIAGNOSTICS & THERAPEUTICSTDT has established procedures to conduct our diagnostic tests on tissue and blood samples supplied from doctors and hospitals West Chester, United States Operational
Nemucore Medical InnovationsNemucore Medical Innovations is clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug Wellesley, United States Operational
RITA Medical SystemsDevelops, manufactures and markets innovative products for patients with solid cancerous or benign tumors Fremont, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • American Medical Systems
  • Arboretum Ventures
  • Aberdare Ventures

Series B and later3 investors entered at this stage

  • PneumRx
  • Boston Scientific
  • Mitsui Global Investment
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States50%
🇬🇧 United Kingdom50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NxThera on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NxThera’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.